A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancers
Phase of Trial: Phase III
Latest Information Update: 11 Jan 2019
At a glance
- Drugs Avatrombopag (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Sponsors Dova Pharmaceuticals
- 25 Jun 2018 Status changed from not yet recruiting to recruiting.
- 13 Mar 2018 Status changed from planning to not yet recruiting.
- 05 Jan 2018 New trial record